As an investment holding entity, Health and Happiness (H&H) International Holdings Limited specializes in the global production and distribution of nutritional and care products designed for families and infants. Its offerings are categorized into several key segments. The Infant Formulas division crafts nutritional formulas for children up to age seven, alongside specialized milk products for pregnant and breastfeeding women. The Probiotic Supplements division provides various forms of probiotics, including sachets, capsules, and tablets, catering to the needs of babies, children, and expecting mothers. Within its Adult Nutrition and Care Products segment, H&H develops and markets a range of items such as vitamins, general health supplements, skincare solutions, and sports nutrition for grown-ups. Complementing its infant offerings, the Other Pediatric Products segment focuses on manufacturing dried baby foods, additional nutritional supplements, and general baby care items. Furthermore, its Pet Nutrition and Care segment creates pet food, health-enhancing supplements, and bone broth products for animals. Beyond these core product lines, the company's activities extend to research, development, and processing of diverse ingredients like meat, fruit, and vegetable powders, as well as candies. It actively researches, develops, manufactures, and sells specialized nutritional foods, manages the marketing and distribution of organic baby foods, and handles the wholesale, retail, import, and export of infant nutritional and personal care products. H&H also engages in the trading and sale of adult vitamins, health supplements, probiotic skincare, and sports nutrition items, while offering online sales platforms, software and IT solutions, and packaging services. Its extensive product portfolio is marketed under well-known brands such as Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII. Established in 1999, the company adopted its current name, Health and Happiness (H&H) International Holdings Limited, in June 2017, having previously operated as Biostime International Holdings Limited. Headquartered in Quarry Bay, Hong Kong, H&H functions as a subsidiary of Biostime Pharmaceuticals (China) Limited.

HKSEConsumer DefensivePackaged Foods
最新資料
HK$21.38
+HK$0.82 · +3.99%
最新資料
HK$21.38
+HK$0.82 · +3.99%
盤中時間採用HKT。市場資料可能有所延遲。
As an investment holding entity, Health and Happiness (H&H) International Holdings Limited specializes in the global production and distribution of nutritional and care products designed for families and infants. Its offerings are categorized into several key segments. The Infant Formulas division crafts nutritional formulas for children up to age seven, alongside specialized milk products for pregnant and breastfeeding women. The Probiotic Supplements division provides various forms of probiotics, including sachets, capsules, and tablets, catering to the needs of babies, children, and expecting mothers. Within its Adult Nutrition and Care Products segment, H&H develops and markets a range of items such as vitamins, general health supplements, skincare solutions, and sports nutrition for grown-ups. Complementing its infant offerings, the Other Pediatric Products segment focuses on manufacturing dried baby foods, additional nutritional supplements, and general baby care items. Furthermore, its Pet Nutrition and Care segment creates pet food, health-enhancing supplements, and bone broth products for animals. Beyond these core product lines, the company's activities extend to research, development, and processing of diverse ingredients like meat, fruit, and vegetable powders, as well as candies. It actively researches, develops, manufactures, and sells specialized nutritional foods, manages the marketing and distribution of organic baby foods, and handles the wholesale, retail, import, and export of infant nutritional and personal care products. H&H also engages in the trading and sale of adult vitamins, health supplements, probiotic skincare, and sports nutrition items, while offering online sales platforms, software and IT solutions, and packaging services. Its extensive product portfolio is marketed under well-known brands such as Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII. Established in 1999, the company adopted its current name, Health and Happiness (H&H) International Holdings Limited, in June 2017, having previously operated as Biostime International Holdings Limited. Headquartered in Quarry Bay, Hong Kong, H&H functions as a subsidiary of Biostime Pharmaceuticals (China) Limited.
日內區間
目前HK$21.38
52週區間
目前HK$21.38
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 143.54億 CNY | 130.52億 CNY | 139.26億 CNY | 127.76億 CNY | 115.48億 CNY |
| 銷貨成本 | 53.9億 CNY | 51.36億 CNY | 54.54億 CNY | 50.72億 CNY | 43億 CNY |
| 毛利 | 89.64億 CNY | 79.16億 CNY | 84.73億 CNY | 77.03億 CNY | 72.48億 CNY |
| 研究與開發 | 2.16億 CNY | 2.43億 CNY | 2.06億 CNY | 1.58億 CNY | 1.44億 CNY |
| 銷售、一般及管理費用 | 70.78億 CNY | 63.49億 CNY | 64.34億 CNY | 59.63億 CNY | 56.68億 CNY |
| 營業費用 | 72.94億 CNY | 63.43億 CNY | 66.41億 CNY | 59.32億 CNY | 56.33億 CNY |
| 利息收入 | 1721.8萬 CNY | 2057.1萬 CNY | 3022.7萬 CNY | 2001.9萬 CNY | 1188.2萬 CNY |
| 利息支出 | 6.86億 CNY | 8.7億 CNY | 8.08億 CNY | 5.3億 CNY | 2.64億 CNY |
| 折舊和攤銷 | 3.11億 CNY | 3.01億 CNY | 3.02億 CNY | 3.11億 CNY | 3.05億 CNY |
| 營業利益 | 16.7億 CNY | 15.72億 CNY | 18.32億 CNY | 16.07億 CNY | 15.12億 CNY |
| 淨利 | 1.96億 CNY | −5372.1萬 CNY | 5.82億 CNY | 6.12億 CNY | 5.08億 CNY |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
HK$0.24
2025年(完整年度)-68.4% 自從 2021
2026年(部分年度):HK$0.98
HK$0.76
2,021
HK$0.42
2,022
HK$0.82
2,023
HK$0.48
2,024
HK$0.24
2,025
HK$0.98
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月10日 | HK$0.82Semi-Annual | 2026年9月11日 | 2026年10月12日 |
股息 | 2026年5月19日 | HK$0.16Semi-Annual | 2026年5月20日 | 2026年7月17日 |
股息 | 2025年9月9日 | HK$0.19Semi-Annual | 2025年9月10日 | 2025年10月17日 |
股息 | 2025年5月15日 | HK$0.05Semi-Annual | 2025年5月16日 | 2025年7月9日 |
股息 | 2024年9月10日 | HK$0.30Semi-Annual | 2024年9月11日 | 2024年10月15日 |
股息 | 2024年5月14日 | HK$0.18Semi-Annual | 2024年5月16日 | 2024年7月10日 |
除息 2026年9月10日
HK$0.82
Semi-Annual
2026年9月11日登記 · 支付日 2026年10月12日
除息 2026年5月19日
HK$0.16
Semi-Annual
2026年5月20日登記 · 支付日 2026年7月17日
除息 2025年9月9日
HK$0.19
Semi-Annual
2025年9月10日登記 · 支付日 2025年10月17日
除息 2025年5月15日
HK$0.05
Semi-Annual
2025年5月16日登記 · 支付日 2025年7月9日
除息 2024年9月10日
HK$0.30
Semi-Annual
2024年9月11日登記 · 支付日 2024年10月15日
除息 2024年5月14日
HK$0.18
Semi-Annual
2024年5月16日登記 · 支付日 2024年7月10日
報告持有此股票曝險的交易所交易基金。
Vanguard Total International Stock ETFVXUS695.82萬0.00%6657億 USD0.05%US$84.54+0.12%
Vanguard FTSE Emerging Markets ETFVWO664.66萬0.00%1685億 USD0.06%US$59.68-0.08%
iShares Core MSCI EAFE ETFIEFA432.87萬0.00%1889.44億 USD0.07%US$96.64+0.48%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS232.85萬0.02%145億 USD0.06%US$154.25+0.07%
iShares MSCI EAFE Small-Cap ETFSCZ205.05萬0.02%128.31億 USD0.40%US$83.95+0.39%
iShares Core MSCI Total International Stock ETFIXUS122.36萬0.00%583.37億 USD0.07%US$94.66+0.10%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM102.04萬0.01%94.46億 USD0.39%US$39.46-0.53%
iShares Core MSCI International Developed Markets ETFIDEV84.32萬0.00%330.46億 USD0.04%US$89.39+0.43%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
iShares Core MSCI EAFE ETFIEFA
Vanguard FTSE All-World ex-US Small-Cap ETFVSS
iShares MSCI EAFE Small-Cap ETFSCZ
iShares Core MSCI Total International Stock ETFIXUS
Dimensional - Emerging Markets Core Equity 2 ETFDFEM
iShares Core MSCI International Developed Markets ETFIDEVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。